Biogeneric Exclusivity Debate: At Least 14 Years Or “Hard And Fast” Combo?

The importance of data exclusivity in ensuring that developers of biologics receive a reasonable return on investment in the face of competition from follow-on products is stressed by the National Venture Capital Association in comments submitted to the House Energy and Commerce Health Subcommittee